Y06036 manufacturers
- Y06036
-
- $38.00
-
2026-05-25
- CAS:1832671-96-1
- Purity: 99.97%
- Supply Ability: 10g
|
| Product Name: | Y06036 | | Synonyms: | Y06036;Benzenesulfonamide, 5-bromo-2-methoxy-N-(6-methoxy-3-methyl-1,2-benzisoxazol-5-yl)-;inhibit,Epigenetic Reader Domain,Inhibitor,Y-06036,Y 06036,Y06036;5-Bromo-2-methoxy-N-(6-methoxy-3-methylbenzo[d]isoxazol-5-yl)benzenesulfonamide;Y06036, 10 mM in DMSO | | CAS: | 1832671-96-1 | | MF: | C16H15BrN2O5S | | MW: | 427.27 | | EINECS: | | | Product Categories: | | | Mol File: | 1832671-96-1.mol |  |
| | Y06036 Chemical Properties |
| storage temp. | Store at -20°C | | solubility | DMSO : 130 mg/mL (304.26 mM) | | form | Solid | | color | Light yellow to yellow |
| | Y06036 Usage And Synthesis |
| Uses | Y06036 is CRPC inhibitor. | | in vivo | Y06036 (50 mg/kg, i.p. injection, 5 times per week, 25 days) demonstrates therapeutic effects in a C4-2B CRPC xenograft tumor model in mice. Y06036 is well tolerated in the treated mice, based on the weight of the animal body and their general behavior[1]. | Animal Model: | Four-week-old male mice (strain: C.B-17/IcrHsd-Prkdcscid for C4-2B) with C4-2B mouse xenograft model[1] | | Dosage: | 50 mg/kg, 100 μL | | Administration: | Intraperitoneal (i.p.) injection, 5 times per week, 25 days | | Result: | Exhibited strong antitumor activities during the 25-day treatment period, with a tumor growth inhibition (TGI) of 70%. |
| | IC 50 | BRD4(1): 82 nM (Kd) |
| | Y06036 Preparation Products And Raw materials |
|